ARCA biopharma, Inc.

Equities

ABIO

US00211Y5069

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-10 pm EDT			5-day change	1st Jan Change
3.47 ^USD	+2.91%		+6.44%	+104.12%

Apr. 25	ARCA biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 19	North American Morning Briefing : Stock Futures -2-	DJ

ARCA biopharma, Inc. Appoints Robert E. Conway to Board of Directors

September 04, 2013 at 08:30 am EDT

ARCA biopharma, Inc. announced that Robert E. Conway, has been appointed to the company's Board of Directors. He will serve on the Audit and Compensation Committees of the Board of Directors. Mr. Conway has over 30 years of executive leadership experience in the pharmaceutical and biotechnology industries.

From 1999 to 2012, he served as the Chief Executive Officer and member of the Board of Directors of Array BioPharma. Prior to joining Array, Mr. Conway was the Chief Operating Officer and Executive Vice President of Hill Top Research, Inc.

Latest news about ARCA biopharma, Inc.

ARCA biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 25	CI
North American Morning Briefing : Stock Futures -2-	Apr. 19	DJ
ARCA biopharma, Inc. Announces Management Changes	Apr. 04	CI
ARCA biopharma, Inc. Announces Separation of Michael Bristow, Chief Executive Officer	Apr. 04	CI
Sector Update: Health Care Stocks Softer Late Afternoon	Apr. 03	MT
Top Midday Gainers	Apr. 03	MT
Sector Update: Health Care Stocks Rise Wednesday Afternoon	Apr. 03	MT
Sector Update: Health Care	Apr. 03	MT
ARCA biopharma, Oruka Therapeutics Announce All-Stock Merger; Shares Surge	Apr. 03	MT
Oruka Therapeutics announced that it expects to receive $275 million in funding	Apr. 02	CI
ARCA biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 01	CI
ARCA biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-18	CI
ARCA biopharma Engages In Strategic Review Process	23-07-21	CI
ARCA biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-07-21	CI
ARCA biopharma Engages in Strategic Review Process	23-07-20	CI
ARCA biopharma, Inc.(NasdaqCM:ABIO) dropped from Russell Microcap Index	23-06-23	CI
ARCA biopharma, Inc.(NasdaqCM:ABIO) dropped from Russell Microcap Value Index	23-06-23	CI
ARCA biopharma, Inc.(NasdaqCM:ABIO) dropped from Russell 3000E Value Index	23-06-23	CI
ARCA biopharma, Inc.(NasdaqCM:ABIO) dropped from Russell 3000E Index	23-06-23	CI
ARCA biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-24	CI
ARCA biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-24	CI
ARCA biopharma, Inc. Announces Departure of Christopher D. Ozeroff as Senior Vice President and General Counsel	23-02-13	CI
ARCA biopharma, Inc. Appoints James Flynn to Board of Directors	22-12-19	CI
Earnings Flash (ABIO) ARCA BIOPHARMA Reports Q3 Loss $-0.16	22-10-28	MT
ARCA biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-10-28	CI

Chart ARCA biopharma, Inc.

Duration

Period

More charts

Company Profile

ARCA biopharma, Inc. is a clinical-stage biopharmaceutical company engaged in developing genetically and other targeted therapies for cardiovascular diseases through a precision medicine approach to drug development. The Company's lead product candidate is Gencaro (bucindolol hydrochloride) for the treatment of atrial fibrillation (AF) in patients with chronic heart failure (HF). Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy. Gencaro is a pharmacogenetically-targeted beta-adrenergic receptor antagonist with mild vasodilator properties that is developing for the treatment of atrial fibrillation in patients with heart failure. Its Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), is a protein therapeutic in clinical development as a potential treatment for patients with COVID-19. It is also evaluating options for development of its assets, including partnering and other strategic options.

Sector

Biotechnology & Medical Research

Calendar

2024-07-30 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ARCA BIOPHARMA, INC.	+104.12%	50.34M
VERTEX PHARMACEUTICALS INCORPORATED	+3.91%	109B
REGENERON PHARMACEUTICALS, INC.	+10.87%	105B
ARGENX SE	+1.28%	22.25B
BIONTECH SE	-13.14%	22.09B
GENMAB A/S	-7.05%	18.68B
WUXI APPTEC CO., LTD.	-38.36%	17.58B
BEIGENE, LTD.	-10.66%	16.85B
NEUROCRINE BIOSCIENCES, INC.	+3.75%	13.76B
SAREPTA THERAPEUTICS, INC.	+36.70%	12.46B

Bio Therapeutic Drugs